Quarterly report · Q1
4544.TEDINET S100OZDP
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥65.3bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥272.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥63.5bn | 2021-04-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | ¥8.6bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | ¥12.2bn | 2021-04-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | ¥8.5bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥47.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥11.9bn | 2021-04-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥8.1bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥11.4bn | 2021-04-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.6bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥29.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥8.3bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥5.6bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | ¥8.3bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥278.3bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥286.6bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥250.2bn | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥132.3bn | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥146.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥146.0bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥140.2bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥118.5bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥39.7bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥46.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥39.7bn | at 2022-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥46.5bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥37.3bn | at 2021-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥43.0bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥6.1bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥55.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥5.6bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥7.3bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥30.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥3.4bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥6.4bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥21.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥8.0bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥98.25 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥519.55 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥146.3 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥98.24 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥519.42 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥146.23 | 2021-04-01 → 2021-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 52.4% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.9% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.3% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥3.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥3.5bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥607m |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥43.4bn |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥43.4bn |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥27m |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥1.7bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥18.5bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥15.0bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥3.5bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥7.0bn |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥7.0bn |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥7.0bn |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥4m |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥440m |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥68.8bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥65.3bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥3.5bn |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥9.2bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-06-30 | −¥2.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-06-30 | −¥2.0bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | −¥502m |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥41.7bn |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥41.7bn |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥14m |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥6.7bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥16.4bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥14.4bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥1.9bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥5.3bn |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥7.4bn |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥7.4bn |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥5m |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥821m |
| —segment total | revenue | 2021-04-01 → 2021-06-30 | ¥65.4bn |
| —segment total | revenue external | 2021-04-01 → 2021-06-30 | ¥63.5bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥2.0bn |
| —segment total | segment profit | 2021-04-01 → 2021-06-30 | ¥12.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 460
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |